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Abstract 
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed to herald a new era 
in the management of type 2 diabetes (T2D), especially for the many patients with T2D who are at high risk for 
cardiovascular and renal events. However, as the evidence in favour of various sodium–glucose transporter-2 inhibi-
tor (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) accumulates, prescriptions of these agents 
continue to stagnate, even among eligible, at-risk patients. By contrast, dipeptidyl peptidase-4 inhibitors (DPP-4i) 
DPP-4i remain more widely used than SGLT2i and GLP-1 RA in these patients, despite a similar cost to SGLT2i and a 
large body of evidence showing no clear benefit on cardiorenal outcomes. We are a group of diabetologists united by 
a shared concern that clinical inertia is preventing these patients from receiving life-saving treatments, as well as plac-
ing them at greater risk of hospitalisation for heart failure and progression of renal disease. We propose a manifesto for 
change, in order to increase uptake of SGLT2i and GLP-1 RA in appropriate patients as a matter of urgency, especially 
those who could be readily switched from an agent without proven cardiorenal benefit. Central to our manifesto is a 
shift from linear treatment algorithms based on HbA1c target setting to parallel, independent considerations of ath-
erosclerotic cardiovascular disease, heart failure and renal risks, in accordance with newly updated guidelines. Finally, 
we call upon all colleagues to play their part in implementing our manifesto at a local level, ensuring that patients do 
not pay a heavy price for continued clinical inertia in T2D.
Keywords: Type 2 diabetes, Cardiorenal protection, Glucose lowering drugs, Clinical inertia
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
It has been 5 years since we first learned that empagliflo-
zin can save lives and substantially reduce cardiovascular 
(CV) risk in patients with type 2 diabetes (T2D) and CV 
disease (CVD) [1]. Subsequently, various cardiovascular 
and renal benefits have been demonstrated for empa-
gliflozin and other agents in the sodium–glucose trans-
porter-2 inhibitor (SGLT2i) [2–13] and glucagon-like 
peptide-1 receptor agonist (GLP-1 RA) [10, 14–19] 
classes. Studies have also now demonstrated these ben-
efits in patients with a more diverse set of diabetic 
comorbidities, including patients with chronic kidney 
disease (CKD; the CREDENCE and DAPA-CKD studies 
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ejection fraction (HFrEF; the DAPA-HF and EMPEROR-
Reduced studies [9, 21]).
In contrast to SGLT2i and GLP-1 RA, numerous CV 
outcomes trials (CVOTs) have pointed to a generally neu-
tral effect with dipeptidyl peptidase-4 inhibitors (DPP-4i) 
[22]. However, despite the high prevalence of cardiorenal 
risk in patients with T2D [23–25], DPP-4i remain more 
widely used than the similarly priced SGLT2i class in 
patients with T2D and cardiorenal comorbidities, includ-
ing CVD, HF and CKD [26–30]. Indeed, the majority of 
eligible patients still do not receive agents for which pro-
tective effects have been proven [26–30], presenting an 
urgent need to increase uptake of SGLT2i and GLP-1 RA 
as part of the standard of care for managing cardiorenal 
risk in patients with T2D [10].
We are a group of diabetologists united by a shared 
concern that patients with T2D are needlessly dying too 
young of CV causes, and suffering from avoidable HF 
hospitalisations (HHF) and progression of CKD. Our 
strong belief is that clinical inertia is the main driver lim-
iting SGLT2i and GLP-1 RA therapy initiation in eligible 
patients with cardiorenal risk; importantly, we note that 
this clinical inertia is contrary to a wealth of evidence 
from CVOTs, and despite updates to clinical guidelines 
that encourage SGLT2i and GLP-1 RA use. We also find 
that low uptake of SGLT2i and GLP-1 RA cannot be pri-
marily explained by pharmacy cost differences, as shown 
by comparisons with DPP-4i, but instead forms part of a 
broader picture of clinical inertia in the management of 
T2D that also affects HbA1c targets.
Here, we summarise clinical inertia as a key barrier to 
increased use of SGLT2i and GLP-1 RA in eligible, at-
risk patients in post-CVOT diabetes care. By doing so, 
we hope to alert the community to the urgency of the 
cardiorenal crisis, and the need to do more to mitigate 
risk in these patients. Plainly, there are many vulnerable 
patients who could today be switched from other agents 
to SGLT2i or GLP-1 RA with life-saving consequences, 
as well as broader benefits for our healthcare systems. In 
our ‘manifesto for change’, we offer practical suggestions 
on how to start to dismantle the barriers standing in the 
way of SGLT2i and GLP-1 RA, and call for all clinicians 
involved in the care of patients with T2D to play their 
part in this mission. Central to our manifesto, we pro-
pose that the unprecedented results of diabetes CVOTs 
may necessitate a rethinking of how we view antidiabetic 
therapy regimens for patients with T2D; in keeping with 
updated clinical guidelines, we suggest that rather than 
choosing between prioritising glycaemic control and car-
diorenal protection, HbA1c targets and cardiorenal risk 
considerations should form distinct, parallel treatment 
algorithms.
We call upon our colleagues to join us in helping to 
drive a positive change in practice at a local level, as we 
face a cardiorenal crisis in T2D. By doing so, we can save 
lives and healthcare resources—preventing some of the 
thousands of deaths and hospitalisations predicted to be 
avoidable with increased use of SGLT2i and GLP-1 RA in 
eligible patients [31].
Out of step with the evidence: the CVOT‑shaped 
hole in diabetes care
More people with T2D die from CVD than any other 
cause [32], and the risk of CV death is particularly pro-
nounced for those with renal comorbidities [25, 33, 34]. 
As death is the ultimate endpoint, mitigating cardiore-
nal risk is a priority in the management of patients with 
T2D who are at high CV and/or renal risk [35, 36]. Since 
2015, with the publication of the EMPA-REG OUT-
COME (empagliflozin) [1] and LEADER (liraglutide) 
[14] CVOTs, we have had the option of including drugs 
with proven CV benefits in glucose-lowering treatment 
regimens [37]. Subsequent disclosures have shown CV 
benefits for certain additional agents within empagliflo-
zin’s SGLT2i class [4, 7] (Fig. 1a) and liraglutide’s GLP-1 
RA class [15–17, 19] (Fig. 1b), as well as suggesting renal 
benefits across both classes [35, 36, 38].
What have we learned from CVOTs?
Reviewing all the diabetes  CVOT data, we can see that 
two oral SGLT2i (empagliflozin [1] and canagliflozin [7]) 
and four injectable GLP-1 RA (liraglutide [14], semaglu-
tide [15], exenatide [19] and dulaglutide [17]) have been 
proven to reduce the risk of 3-point major adverse CV 
events (3P-MACE; a composite of CV death, myocar-
dial infarction (MI) and stroke), the prespecified primary 
outcome, in their respective CVOT populations. In addi-
tion, secondary and exploratory CV and HF outcomes 
in CVOTs have suggested that empagliflozin, liraglutide 
and oral semaglutide reduce the risk of CV death [1, 14, 
16]; injectable semaglutide and dulaglutide reduce the 
risk of nonfatal stroke [15, 17]; and all SGLT2i reduce the 
risk of HHF [3, 4, 7, 11] (now also confirmed in the dedi-
cated HFrEF studies DAPA-HF and EMPEROR-Reduced, 
which both included patients with and without T2D [9, 
21]).
Other secondary and exploratory outcomes in CVOTs 
have also suggested additional benefits of SGLT2i and 
GLP-1 RA that may be of particular relevance to patients 
with CVD, including slowed progression of albuminu-
ria [39, 40], and reductions in blood pressure and body 
weight [13, 32]. For SGLT2i, CVOTs and other studies 
have consistently pointed to strong protection from renal 
function decline compared with placebo [10, 12, 38].
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Fig. 1 Cardiorenal and mortality benefits reported for SGLT2i and GLP-1 RA. a SGLT2i. CVOTs for empagliflozin, canagliflozin, dapagliflozin and 
ertugliflozin have all pointed to beneficial effects on HHF and renal function outcomes [2–5, 7, 11, 13], either in a population with T2D and 
established CVD, or in a broader population also including patients with T2D and high CV risk. Renal benefits included slower progression of 
renal function decline and, where reported, improved albuminuria outcomes. In addition, empagliflozin and canagliflozin CVOTs demonstrated 
a reduction in 3P-MACE, while empagliflozin alone showed reductions in CV death and death by any cause [1, 7]. Note that in some cases 
benefits were shown in exploratory analyses. Dedicated renal and heart HF studies are also shedding light on cardiorenal benefits with SGLT2i. In 
CREDENCE, canagliflozin reduced HHF and renal events in patients with T2D and CKD (and showed a trend towards reduced CV deaths that did 
reach significance) [6], while in DAPA-HF, CV death, HHF and death by any cause were all reduced with dapagliflozin in patients with HFrEF, with or 
without T2D [9]. While this manuscript was under review, new publications have also shown that dapagliflozin improved a composite of renal and 
CV outcomes in patients with CKD, with or without T2D, in DAPA-CKD [20], and that empagliflozin reduced the risk of a composite of CV death or 
HHF in patients with HFrEF, with or without T2D, in EMPEROR-Reduced [21] (not shown). b GLP-1 RA. Some, but not all, GLP-1 RA CVOTs have shown 
cardiorenal benefits in patients with T2D and established CVD or high CV risk. Among injectable GLP-1 RA, liraglutide, semaglutide and dulaglutide 
CVOTs have all shown benefits in 3P-MACE and albuminuria outcomes [14, 15, 17, 18, 122, 123]. In addition, liraglutide reduced the risks of CV death 
and death by any cause, while semaglutide and dulaglutide reduced the risk of stroke. Once-weekly exenatide showed a trend towards a 3P-MACE 
benefit that did not reach significance in its CVOT, and also suggested reduced risks of death by any cause and albuminuria [19, 124]. Finally, a CVOT 
on the oral formulation of semaglutide suggested reduced risks of CV death and death by any cause [16]. For all CVOTs, patients in both placebo 
and treatment arms also received standard of care. Outcome definitions and inclusion criteria varied between CVOTs. Not all outcomes were 
primary outcomes, and findings may in some cases be of nominal significance only due to multiple testing, e.g. position in a prespecified hierarchy 
of statistical tests. Only marketed medications are shown
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Unlike SGLT2i and GLP-1 RA, CVOTs for DPP-4i 
have universally shown no benefit for primary and other 
ASCVD outcomes (although all agents have demon-
strated safety for these outcomes) [22]. For secondary 
cardiorenal outcomes, DPP-4i CVOTs have indicated 
generally neutral effects, with possible exceptions of 
modest albuminuria benefits and increased HHF risks 
suggested in some, but not all, studies [22].
The remarkable cardiorenal benefits seen with SGLT2i 
are also reflected in real-world evidence studies, which 
encompass more diverse patient characteristics and cap-
ture the experience of routine clinical practice. In newly 
presented 3-year interim data from the EMPRISE real-
world evidence study, patients were 48% less likely to 
die during the study period when taking empagliflozin 
compared with DPP-4i, and 58% less likely to be hospi-
talised for HF [41]. Compared with GLP-1 RA, patients 
were 37% less likely to be hospitalised for HF. Similarly, 
the CVD-REAL studies have shown that a composite of 
HHF and all-cause death is substantially reduced with 
the SGLT2i class compared with other glucose-lowering 
drugs [42, 43] or DPP-4i [44]. Benefits have also been 
suggested for renal outcomes with SGLT2i in real-world 
studies, including when compared with other glucose-
lowering drugs (CVD REAL 3 [45]) or specifically with 
DPP-4i (a cohort study of ~ 60,000 new initiators in Den-
mark, Norway and Sweden [46]).
EMPRISE and the CVD-REAL series have to date 
cumulatively encompassed more than 400,000 patients 
treated with SGLT2i, with a broad range of CV risk at 
baseline. In both EMPRISE and CVD-REAL, a majority 
of patients did not have established CVD or HF at base-
line [41–43], suggesting that SGLT2i provide cardiorenal 
protection from very early in the progression of CVD.
Real-world data for cardiorenal outcomes with GLP-1 
RA are more limited, beyond the aforementioned 
EMPRISE study. Three-year outcomes from EMPRISE 
show that MI rates were similar between GLP-1 RA 
and empagliflozin, but that HHF was more common 
with GLP-1 RA, while stroke was less common [41]. In 
a 2014–2018 study of patients with T2D in North-East 
Italy, 4298 GLP-1 RA initiators were propensity matched 
to the same number of SGLT2i initiators. The study 
found that GLP-1 RA were associated with higher rates 
of 3P-MACE, MI, HHF and hospitalisation for any CV 
cause than SGLT2i [47]. Evidence for renal outcomes can 
be found in a cohort study covering 38,731 new users of 
GLP-1 RA in Sweden, Denmark and Norway, propensity 
matched to new users of DPP-4i [48]. GLP-1 RA were 
associated with 27% reductions in both progression to 
renal replacement therapy and hospitalisation for renal 
causes [48].
The evidence from CVOTs—and supporting, con-
firmatory data from real-world evidence studies—has 
led guidelines to advocate increasing the use of SGLT2i 
and GLP-1 RA [35, 36, 49–51] and, from the authors’ 
perspective, profoundly changed our clinical practice. 
However, prescribing evidence from North America 
and Europe suggests that most eligible patients are still 
not receiving these agents [26–30] (Fig. 2), despite their 
proven cardiorenal benefits and the urgency of address-
ing CV and renal risk as comorbidities that pose the big-
gest threat to life in T2D.
Why do some SGLT2i and GLP‑1 RA show cardiorenal 
benefits in diabetes CVOTs?
The mechanisms underlying cardiorenal benefits with 
SGLT2i and GLP-1 RA in patients with T2D are not yet 
certain, although several have been proposed.
For SGLT2i, suggested mechanisms include (but are 
not limited to): reduced levels of plasma plasminogen 
activator inhibitor-1 (PAI-1), leading to visceral fat area 
loss and a restored adipokine balance [52]; beneficial 
vascular effects via anti-inflammatory mechanisms, as 
indicated by reduced high-sensitivity c-reactive protein 
(hs-CRP) [53]; energy repletion and reduced inflam-
mation mediated by AMPK, together with reduced 
autophagy and lower levels of CD36 and cardiotoxic 
lipids, in the heart [54, 55]; haemodynamic volume 
effects [56]; improved cardiac remodelling, increased 
provascular progenitor cells and decreased ischaemia/
reperfusion injury [57]; and off-target inhibition of the 
cardiac  Na+/H+ exchanger [58].
Proposed mechanisms for GLP-1 RA include an anti-
atherothrombotic effect, as well as amelioration of 
inflammatory markers, resulting in the enhanced retarda-
tion of atherosclerosis [59, 60], together with an antihy-
pertensive effect [61]. This may occur via antiproliferative 
actions on vascular smooth muscle cells and endothe-
lial cells, reductions in oxidative stress, and increases in 
nitric oxide generation, microvascular recruitment and 
microvascular blood flow [61].
An urgent need to save more lives with SGLT2i 
and GLP‑1 RA
According to recent surveys of prescribing habits, only 
modest increases in SGLT2i and GLP-1 RA use have 
been observed during the CVOT era; to compound the 
issue, prescribing rates for the two classes, as new agents, 
have historically been  low [26–29]. For example, among 
several hundred thousand US patients with T2D and 
established CVD who received glucose-lowering drugs 
between 2014 and 2018, the proportion taking SGLT2i 
did increase after the publication of EMPA-REG OUT-
COME, but only from 4.1% in 2015 to 7.2% in 2018 [26]. 
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Similarly, GLP-1 RA use increased after the publication 
of LEADER, but only from 4.2 to 8.2% [26]. Thus, the 
majority of patients with T2D and established CVD in the 
US were not given a glucose-lowering drug with proven 
CV benefits as many as 3 years after the cardioprotective 
effects of empagliflozin became known. It is particularly 
unfortunate that the historical use of SGLT2i was par-
ticularly low in patients with HF [62], who may stand 
to benefit most from the reduction in HHF observed in 
CVOTs. For patients with T2D, HF is a common comor-
bidity with a poor prognosis, and a major cause of mor-
tality [63].
Uptake of SGLT2i and GLP-1 RA may be even lower 
for patients with CV comorbidities in Europe than in 
the US, according to national registry data from Den-
mark. Across all patients with T2D, the registry data 
show that SGLT2i had only a 4% share of all antidiabetic 
agents by 2017, with GLP-1 RA faring little better, at 8% 
[27]. Among new initiators of these agents between 2014 
and 2017, only 28–29% had established atherosclerotic 
CVD (ASCVD) [28]. As this is a similar prevalence to the 
estimated 20–25% of patients with early T2D in Denmark 
who have ASCVD, it seems that therapy choices were not 
optimally targeted to the patients best supported by evi-
dence from CVOTs [28].
By contrast, despite accumulating CVOT evidence that 
DPP-4i do not provide CV protection, US prescribers 
maintained a preference for DPP-4i vs SGLT2i in patients 
with T2D and established CVD [26, 29, 30] (Fig.  2). 
Indeed, parallel to the emergence of such data, the pro-
portion of patients receiving DPP-4i remained stable 
from 2015 to 2018, at 12% [26]. Consistent with this find-
ing, a 2014–2017 study focusing on cardiology centres 
found that patients with established ASCVD or at high 
risk of CV events were around threefold more likely to be 
taking DPP-4i than SGLT2i or GLP-1 RA [31, 37]; while 
a study focusing on primary care from January 2013 to 
April 2016 found that 23% of >250,000  US patients with 
T2D received DPP-4i second-line to metformin, com-
pared with 4% receiving SGLT2i and 6% receiving GLP-1 
RA [64]. Even by 2019, patients with T2D and CVD were 
Fig. 2 Most patients with T2D and CVD are not prescribed SGLT2i or GLP-1 RA. Data from the US and Denmark show clinical inertia in prescribing 
SGLT2i or GLP-1 RA, with only modest increases following the disclosures of the first CVOTs to show cardiorenal benefits, in September 2015 
(EMPA-REG OUTCOME) and June 2016 (LEADER), respectively. Summaries are shown of data from the US Optum claims database between 2014 and 
2018 [26, 31]; a rolling 3-year window study of clinical records from 20 US healthcare organisations, with the oldest cohort from Q1 2013 to Q1 2016 
and the most recent cohort from Q1 2016 to 2019 [29, 30]; a nationwide cohort of new initiators of T2D therapies in Denmark from 2014 and 2017 
[28]; and a nationwide registry of medicine utilisation in Denmark from 1996 to 2017, which did not include patient-level data [27]. Contemporary 
costs of SGLT2i, GLP-1 RA and DPP-4i in 2017, the most recent year captured by all the studies, show that pricing does not seem to explain therapy 
preferences. US prices are median National Average Drug Acquisition Cost reference data per day for empagliflozin, liraglutide and sitagliptin [73]. 
Other agents in each class were similarly priced. For Denmark, mean prices for a defined daily dose are shown across each class [27]
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no more likely to be taking SGLT2i or GLP-1 RA than 
patients without CVD [30].
In Denmark, DPP-4i accounted for 5% of antidiabetic 
agents given to patients in 2017 [27], with the share of 
new initiators remaining stable from 2014 [28]. Although 
new initiators of SGLT2i sharply increased following 
EMPA-REG OUTCOME, the ratio of SGLT2i:DPP-4i 
new initiators between 2014 and 2017 was similar regard-
less of whether patients had ASCVD [28]. This suggests 
that even where SGLT2i share is increasing, cardiopro-
tective benefits are not fully appreciated by prescrib-
ers [28]. Instead, obesity seemed to be a much stronger 
driver of SGLT2i preference over DPP-4i [28].
We were even more troubled by the usage rates of 
SGLT2i in a population that may have most to gain, 
namely patients with chronic HF (CHF). Fewer US 
patients with T2D, established CVD and CHF were tak-
ing SGLT2i than GLP-1 RA or DPP-4i in 2018 [26], even 
though updated ADA guidelines for that year singled 
out SGLT2i as reducing the risks of HHF in CVOTs [65]. 
Among US patients fitting the eligibility criteria for the 
EMPA-REG OUTCOME trial, the presence of HF actu-
ally reduced the likelihood that a patient would be given 
SGLT2i [31]. Similarly, among new initiators in Denmark 
between 2014 and 2017, patients with CHF were more 
likely to be prescribed DPP-4i than SGLT2i [28]. Accord-
ing to a Scandinavian cohort study, the risk of hospitali-
sation for HF is robustly associated with T2D, even when 
patients achieve targets for HbA1c, low-density lipopro-
tein cholesterol, albuminuria, smoking and BP [23].
Another at-risk population that causes us particu-
lar concern is the older patient group. Although inci-
dence rates of HHF and mortality are both substantially 
higher in older than younger patients [41, 66], prescrip-
tion data show that older age is associated with DPP-4i 
use in preference to SGLT2i [26, 28, 31]. This may be 
due to increased prevalence of renal impairment in older 
patients (especially those with T2D [67]), as patients with 
CKD were also less likely to receive SGLT2i than GLP-1 
RA or DPP-4i [26, 28], in accordance with prescribing 
information guidance regarding patients with impaired 
renal function [68]. However, we note that CVOTs have 
suggested a strong reduction in the progression of CKD 
with SGLT2i [2, 5, 8], subsequently proven in renal out-
comes studies [6, 20]. Furthermore, both EMPA-REG 
OUTCOME [69] and EMPRISE [66] have reported cardi-
orenal benefits with empagliflozin for older patients. For 
example, a subgroup analysis of EMPA-REG OUTCOME 
found significantly increased protection from 3P-MACE 
in elderly (age ≥ 65  years; 45% of the study cohort) vs 
non-elderly patients [67]. The risk of MACE, HF or mor-
tality in patients with T2D and CKD is also most ele-
vated in older patients, suggesting that these patients are 
particularly in need of agents that reduce the risk of such 
events [70, 71]. An individualised approach to treatment 
is warranted for older patients with T2D, balancing car-
diorenal comorbidities alongside health status, life expec-
tancy and hyperglycaemia, while paying careful attention 
to the risk of hypoglycaemia [67].
What is the impact of the continued reluctance to use 
SGLT2i or GLP-1 RA in patients with T2D with estab-
lished CVD or at high CV risk? It has been estimated that 
if all patients meeting the inclusion criteria of EMPA-
REG OUTCOME were to take SGLT2i, an additional 920 
deaths, 780 CV deaths and 510 HHF could be avoided 
per 100,000 patients per year [31]. An even greater num-
ber of patients fit the inclusion criteria for other SGLT2i 
CVOTs, with a recent meta-analysis finding that 50% of 
patients with T2D across multiple countries fulfil the 
criteria for the dapagliflozin CVOT DECLARE-TIMI 58 
[72]. Treating all LEADER-eligible patients with GLP-1 
RA could avoid an estimated 300 MIs and 400 CV deaths 
per 100,000 patients per year [31]. For older patients, the 
impact may be even more stark; in the EMPRISE cohort, 
patients ≥ 66  years taking SGLT2i had 757 fewer deaths 
and 996 fewer HHF per 100,000 patient-years, compared 
with propensity matched patients taking DPP-4i [66]. 
We note that less than 50% of these older patients in 
EMPRISE had a history of CVD at baseline, and only 12% 
had established HF [66].
What are the barriers to change?
We believe that all clinicians want what is best for their 
patients, so it is important to understand the barriers that 
are preventing SGLT2is and GLP-1 RA from being given 
to more patients. In our discussions, we identified several 
possible barriers; importantly, we suggest that clinical 
inertia rather than cost may be the main driver of contin-
ued preference for other agents in these patients.
We concede that the influence of cost will vary accord-
ing to local reimbursement, but note that pricing for 
SGLT2i and DPP-4i at the time of the studies described 
here were similar to one another in the US [73] and Den-
mark [27] (Fig. 2), and yet prescribers maintained a clear 
preference for DPP-4i [26–28]. By contrast, clinical iner-
tia is well established as a barrier to treatment intensifica-
tion in patients with high HbA1c [74–80], and we suggest 
that this same phenomenon also translates to the man-
agement of cardiorenal risk in patients with T2D [81, 82].
Clinical inertia: the prime suspect
If clinical inertia is the most significant barrier, what 
could be driving this inertia  in the face of the weight 
of evidence from CVOTs? In its simplest form, iner-
tia is merely an aversion to change; in medicine, this 
can be well founded, with many healthcare providers 
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understandably preferring to use treatments with which 
they are more experienced, as they are reassured on the 
predictability of safety and efficacy, and confident in the 
practicalities of how to prescribe them. Such tendencies 
naturally penalise SGLT2i and GLP-1 RA as relatively 
new treatment classes, despite the evidence favouring 
their use. However, we believe that lack of awareness, 
competing priorities, and siloed specialities may all also 
have important roles in driving clinical inertia in T2D 
(Fig. 3).
It is our view that not all colleagues are fully aware of 
the cardiorenal benefits shown in some CVOTs, nor 
of the central role of CV and renal risk in outcomes for 
patients with T2D; this may be especially true of primary 
care practitioners (PCPs), who necessarily have fewer 
opportunities for education on CVD, renal disease and 
diabetes than specialists, and may have limited knowl-
edge on evidence for treatment outcomes [83]. Indeed, 
clinical inertia in glycaemic control has been shown to 
be more pronounced in PCPs than specialists [77], and 
glucose levels as well as CV risk factors have been shown 
to be better controlled with earlier referral to specialist 
care [84]. That said, we note that clinical inertia on glu-
cose control nevertheless remains quite substantial even 
among specialists [77], and this may also be the case 
for cardiorenal risk management, especially given a his-
torical pattern of insufficient attention to CV risk in pre-
CVOT diabetes guidelines [85].
We have seen that the opportunities for interdiscipli-
nary collaboration are limited in many settings, which 
means that PCPs and endocrinologists may not benefit 
from the relevant knowledge of cardiologists and renal 
specialists. Related to this, CVD [24] and CKD [86, 87] 
may be underdiagnosed in patients with T2D. Involving 
multiple disciplines has been shown to produce desir-
able outcomes in weight management [88] and glycaemic 
control [84] in T2D; and we believe that a multidiscipli-
nary approach can be similarly beneficial in the manage-
ment of cardiorenal risk.
To compound insufficient education on CVOTs, phy-
sicians face competing priorities from more apparent 
risks such as hypoglycaemia and obesity [51]. Indeed, we 
have observed that obesity is a bigger driver of treatment 
choice than CV or renal risk when comparing SGLT2i, 
GLP-1 RA and DPP-4i [28]. Obesity is very obvious to 
both clinicians and patients; the challenge is to ensure 
that the less visual risks of CVD, HF and renal disease 
[24, 89] have sufficient prominence in treatment consid-
erations, given their contributions to mortality in T2D, 
and CVOT evidence on risk mitigation. The challenge of 
competing comorbidities is further complicated by the 
need for physicians to be aware of the interconnected 
risks within the cardiorenal–metabolic axis, such as the 
elevated risk of MACE and HF in patients with T2D and 
CKD [70, 90].
Fig. 3 Drivers of clinical inertia in the management of cardiorenal risk in T2D. We argue that the slow uptake of SGLT2i and GLP-1 RA following 
CVOT disclosures can be attributed to clinical inertia. We suggest several factors that may be responsible for driving this inertia; each will need 
to be addressed if we are to ensure that eligible, at-risk patients are to benefit from the risk reductions proven in CVOTs, and now emerging from 
dedicated HF and renal studies
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For many patients, their treatment journey within the 
healthcare system precludes the possibility of regular 
treatment re-evaluations, even if their level of cardiore-
nal risk is increasing. Delay in treatment intensification 
is well characterised for managing hyperglycaemia [79]. 
Both CV [24] and renal disease [2] are known to progress 
as duration of T2D increases, but infrequent treatment 
re-evaluations may mean that there is a lack of oppor-
tunity to reassess whether the addition of an agent with 
proven CV or renal benefits is warranted due to new 
onset or progression of cardiorenal comorbidities.
Balancing risks and benefits—who is ‘the right patient’?
One driver of clinical inertia may be the perceived bal-
ance between cardiorenal benefit and risk due to the 
safety profile or potential for undertreatment. In particu-
lar, for SGLT2i, a consistent signal has been seen for uro-
genital infections and rare but potentially serious events 
of diabetic ketoacidosis (DKA), with especially worri-
some cases that have atypical presentation (i.e. non-ele-
vated glucose levels) and so may not be readily detected 
[91].
It is entirely proper to be cautious about these aspects 
of SGLT2i, but we believe that the risks are outweighed 
by the considerable cardiorenal benefits of these agents. 
Although relatively common, urogenital infections 
observed in patients on SGLT2i are typically mild-to-
moderate and clinically manageable [91]. DKA events 
with SGLT2i are rare, but should be recognised as poten-
tially very serious [92, 93]. Due to the elevated risk of 
DKA with SGLT2i in patients with type 1 diabetes [92, 
93], clinicians should be alert to the possibility of latent 
autoimmune diabetes in patients presumed to have T2D. 
For patients with bona fide T2D, the risks of DKA are 
lower and can be mitigated by interrupting use for sur-
gery, during prolonged periods of starvation, or in the 
setting of recurrent illness [92, 93]. Nevertheless, cli-
nicians should be fully appraised of DKA guidance in 
SGLT2i prescribing information, including clinical set-
tings where monitoring is recommended. So long as 
these risks are mitigated and monitored, we believe that 
the safety profiles of SGLT2i should be viewed as broadly 
favourable, and certainly not of sufficient concern to jus-
tify depriving eligible patients of the cardiorenal protec-
tive effects of these agents.
Reluctance to use SGLT2i in patients with impaired 
renal function may often be due to prescribing restric-
tions [68], in which case GLP-1 RA are preferred for 
patients with ASCVD or renal risk [36, 51]. In other 
cases, physicians may nevertheless be concerned that 
hyperglycaemic efficacy is reduced with SGLT2i in 
patients with impaired renal function, even if the esti-
mated glomerular filtration rate (eGFR) remains within 
the permitted prescribing range [94]. However, this over-
looks the benefits of SGLT2i for cardiorenal outcomes, 
which are independent of glycaemic efficacy and seen 
even in patients with CKD [6, 38]. Furthermore, we do 
not believe that physicians are compelled to choose 
between undertreatment for hyperglycaemia and under-
treatment for cardiorenal risk; instead, SGLT2i should be 
maintained while adding a further agent to better control 
HbA1c levels, as recommended by current guidelines [36, 
51].
Beyond patients with diagnosed CKD, the overall low 
level of use of SGLT2i and GLP-1 RA in patients with 
T2D suggests that many who have undiagnosed CKD may 
also not be receiving optimal care. A recent retrospective 
study of 136,157 patients with T2D in the US between 
2011 and 2019 found that more than half of patients with 
micro- or macroalbuminuria were not diagnosed with 
CKD, a proportion that did not meaningfully improve 
across the study period [86]. Similarly, while awareness 
among physicians of CKD in patients with renal impair-
ment showed a modest improvement over the decade, 
40% of patients with eGFR 45–59 ml/min/1.73 m2 were 
still not diagnosed with CKD by 2016–2019 [86]; even for 
patients with the more severe renal impairment of eGFR 
30–44 ml/min/1.73m2, 15% remained undiagnosed with 
CKD, despite these laboratory values being present in 
their electronic medical records [86]. Diagnosis rates in 
primary care may be even lower; in a retrospective obser-
vational study of 9307 patients with T2D in primary care 
in the US between 2011 and 2012, only 12% of patients 
meeting the criteria set out in national guidelines were 
diagnosed with CKD [87]. For patients with moderate-
to-severe (Stage 3–5) CKD, the rate of diagnosis was 
higher, but still only 22% [87]. Therefore, identifying ‘the 
right patient’ for treatment with SGLT2i or GLP-1 RA 
will need to involve improved diagnosis of CKD in order 
to provide renal protection to the broadest set of eligible 
patients.
Does saving lives cost more money?
We accept that reimbursement barriers are highly vari-
able between and within countries, and that in some 
cases the challenge of reimbursement may tie clinicians’ 
hands, preventing some patients from accessing the opti-
mal drug for their clinical profile [95, 96]. Where reim-
bursement does not favour SGLT2i and GLP-1 RA, there 
may be a gap in  reimbursement authorities sufficiently 
acknowledging the relevance of cardiorenal risk to out-
comes in choosing antidiabetic agents.
Indeed, the full cost of T2D to the healthcare system 
encompasses considerable healthcare resource uti-
lisation and expenditure across the full spectrum of 
comorbidities, all of which need to be considered when 
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justifying the cost effectiveness of a treatment. For 
example, increased protection from HF in patients on 
SGLT2i has been shown to considerably reduce hospi-
talisation costs in patients with T2D [97–99] (Fig.  4a), 
while slowed progression of renal disease with SGLT2i 
can amount to tremendous cost savings, given the large 
expenses involved in renal care [89, 100, 101]. In  the 
US, the potential average saving in renal care costs in an 
b
a
Fig. 4 Savings to healthcare costs and resource utilisation with SGLT2i. a Savings across US insured populations with T2D. Two-year interim data 
from the EMPRISE real-world evidence study has measured the cost of care and healthcare resource utilisation for new initiators of empagliflozin 
vs DPP-4i in two commercial claims databases plus Medicare patients between August 2014 and September 2016, with an average of 5.4 months 
follow-up. Healthcare resource utilisation data were available for 17,549 patients in each arm matched 1:1 by propensity scoring, and showed ≥ 20% 
reductions in the numbers of hospitalisations and ER visits with empagliflozin per member per year (PMPY) [125]. Cost data were available for 2928 
patients in each arm matched 1:1 by propensity scoring, and showed substantial savings with empagliflozin across the full cohort [126]. A model 
based on data from the CREDENCE renal outcomes study estimated that the total cost saving for a US insured population with T2D and CKD would 
be nearly $2000 PMPY when adding canagliflozin to standard of care [100]. b Savings per affected patient in the US, UK and Germany. Cost data 
from the US [100, 103], UK [101, 127] and Germany [102] showing the healthcare expenditure associated with HF and CKD. As expected, costs for 
the US are notably higher than in Europe; however, even in the UK and Germany expenditure is substantial
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insured population with diabetic kidney disease has been 
modelled as > $1000 per member per year [100] (Fig. 4a), 
consistent with the estimated annual cost burden of 
each patient with CKD to the UK’s NHS of £795 [101] 
(Fig.  4b). Estimates for annual costs for each affected 
patient with CHF range from €3912 for a German man in 
his 60s with T2D [102] to $31,000 for a Medicare patient 
in the US [103]; for end-stage renal disease, estimates 
range from £27,000 for dialysis expenditure alone in the 
UK to more than $100,000 in the US for the total cost 
of care [100] (Fig. 4b). For both HF and CKD, the pres-
ence of T2D makes care more expensive and resource 
intensive, and costs and resource utilisation also become 
higher with disease progression [89, 104]. Therefore, 
reducing HF hospitalisations and the progression of CKD 
with SGLT2i has the potential to be highly cost effective, 
especially in those markets where drug prices are similar 
between SGLT2i and DPP-4i classes [98, 99, 105].
Can we keep up with the fast pace of progress?
Non-adherence to guidelines has been dubbed ‘the 
enemy of evidence-based practice’ [106]. However, the 
constant release of data from studies evaluating cardio-
renal outcomes with SGLT2i and GLP-1 RA can render 
guidelines out-of-date soon after publication. Conversely, 
frequent updates to guidelines to keep up with emerg-
ing data can be a challenge for clinicians, especially non-
specialists, who may struggle to keep abreast of the latest 
recommendations [107]. Further difficulties can arise 
when guidelines are issued by different organisations 
without always being in agreement [108].
In 2018, it was estimated that only 14% of US patients 
with T2D and CVD benefited from therapy choices 
rooted in the 2019 ADA guidelines, highlighting the dis-
cordance between fast-evolving evidence and slower-to-
change practice [29].
A manifesto to defeat clinical inertia
We believe that change is urgently needed to reduce 
clinical inertia and surmount other barriers to using 
agents with optimal cardiorenal benefits for patients with 
T2D. We would like to suggest several readily achievable 
approaches towards this goal, in our ‘manifesto’ to save 
lives, reduce the occurrence of CV events and HF hos-
pitalisations, and slow the progression of renal disease 
for our patients (Fig.  5a). Our suggestions are based on 
our own clinical experience, together with observations 
reported in the literature discussing clinical inertia more 
widely in T2D, and our perspective on the latest guide-
line updates in light of CVOTs.
Advocate for post‑CVOT treatment pathways that separate 
HbA1c targets from cardiorenal protection
The latest international guidelines have reimagined treat-
ment pathways for glucose-lowering drugs in T2D, sepa-
rating HbA1c from cardiorenal risk, including distinct 
considerations for ASCVD, HF and CKD [35, 36, 50, 
51] (Fig.  5b). This is a substantial shift from pre-CVOT 
guidelines, which we believe did not pay sufficient heed 
to CV risk in patients with T2D [85]. We cannot over-
state how crucial we think it is for this multi-faceted, 
parallel approach to treatment selection to become the 
standard of care. As the guidelines acknowledge, it is 
clear from CVOTs that reduced risks of cardiorenal 
events are independent of glucose control. Therefore, the 
historical linear approach to treatment intensification 
based on HbA1c targets is a legacy of the pre-CVOT era, 
when independent cardiorenal benefits were not known, 
and should now be consigned to the past.
Learnings from CVOTs also necessitate a rethinking 
of when to re-evaluate a patient’s treatment regimen. 
More opportunities will be needed to assess cardiorenal 
risk, so that missed glucose targets are not the only trig-
ger for re-evaluation. We have a particular concern that 
long-standing patients may be most vulnerable to clinical 
inertia and least likely to benefit from updated guidelines. 
These patients may not have regular treatment evalua-
tion schedules, and treating physicians may be reluctant 
to change antidiabetic treatments when well-maintained 
glucose control has been established over a period of 
time, irrespective of the cardiorenal risks presented. As 
cardiorenal disease is expected to progress over time with 
duration of T2D, it is essential that treatment for these 
patients is re-evaluated to consider prescribing SGLT2i 
or GLP-1 RA according to the balance of clinical risk fac-
tors for ASCVD, HF and CKD.
For new patients, early selection of an agent with cardi-
orenal benefits will reduce the requirement for later eval-
uations. Guidelines recommend that cardiorenal risk is 
considered from first add-on to metformin [36, 51] (or, in 
recommendations from the European Society of Cardiol-
ogy (ESC), from first diagnosis of T2D, although this has 
been controversial and for some patients would trans-
late to unlicensed SGLT2i or GLP-1 RA monotherapy 
[50, 108]). Early in the course of T2D, satisfaction with 
HbA1c levels may mean that physicians are less likely to 
add on an SGLT2i or GLP-1 RA, but we note that a sub-
stantial burden of CVD is present in patients with T2D 
and HbA1c < 7.5% [32]. For example, a nationwide diabe-
tes register in Scotland showed that 66% of patients with 
T2D on metformin monotherapy were at very high CV 
risk [109].
For patients who have already intensified their treat-
ment beyond metformin monotherapy, managing 
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cardiorenal risk may involve a switch from a neutral 
drug to one with proven protection, thereby reduc-
ing the burden of polypharmacy. Switching from other 
agents to SGLT2i or GLP-1 RA will be a key indicator 
of the success of our manifesto. Although we recognise 
the physician’s natural intuition not to change medica-
tion in a patient with well-controlled Hb1Ac, for the 
many patients with on-target HbA1c where CV risk, HF 
a
b
Fig. 5 The clinical inertia crisis: a manifesto. a Our manifesto for change. We have set out needed actions to tackle clinical inertia in T2D in a 
‘manifesto’ to change practice, including seven steps that colleagues can adopt to change local prescribing habits, so that more lives are saved 
and cardiorenal events avoided with appropriate use of SGLT2i and GLP-1 RA. b Rethinking treatment algorithms to separate the management of 
cardiorenal risk from HbA1c targets. Central to our manifesto is a wider adoption of the new approach taken by ADA, EASD and ESC guidelines [36, 
50, 51] to treatment algorithms of antidiabetic agents. Rather than only add on treatments when HbA1c targets are exceeded, updated guidelines 
recommend that ASCVD, HF and renal risks should be considered independently of HbA1c. For patients with established ASCVD or presenting 
indicators of high ASCVD risk, the treatment regimen should be adapted by add-on or switch to incorporate a SGLT2i or GLP-1 RA with proven CV 
benefits. For patients with HF, notably HFrEF with LVEF < 45%, or CKD, an SGLT2i with proven benefit should be incorporated by add-on or switch, so 
long as not contraindicated e.g. due to renal function lower than indicated in prescribing information. CKD can be defined as estimated glomerular 
filtration rate (eGFR) < 60 ml/min/1.73 m2 and/or urinary albumin–creatinine ratio (UACR) > 30 mg/g (and especially if > 300 mg/g). Among SGLT2i, 
according to current European Union prescribing information, dapagliflozin, empagliflozin and ertugliflozin should not be initiated below 60 ml/
min/1.73 m2 (and stopped if persistently below 45 ml/min/1.73 m2), while canagliflozin should only be used below 45 ml/min/1.73 m2 for patients 
with UACR ˃ 300 mg/g, and should not be initiated below 30 ml/min/1.73 m2. Prescribing information in the United States has some differences; 
ertugliflozin is not recommended in patients with an eGFR below 60 ml/min/1.73 m2, while canagliflozin, dapagliflozin and empagliflozin may be 
initiated below 60 ml/min/1.73 m2, but should be discontinued if persistently below 45 ml/min/1.73 m2 (with the exception of dapagliflozin in 
patients with HFrEF, with or without T2D, where use is supported for eGFR ≥ 30 ml/min/1.73 m2). If SGLT2i cannot be used, a GLP-1 RA with proven 
benefit should be considered to improve renal outcomes for patients with CKD
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or CKD is a factor [32], it may be that poorly controlled 
cardiorenal disease is  being missed. For this reason, we 
believe that treatment algorithms should very clearly 
encourage such patients to be switched as a matter of 
urgency to SGLT2i or GLP-1 RA.
Be a voice for local guidelines that are ambitious 
for patients and regularly updated
As we have seen with the rapid emergence of CVOT data, 
without regular updates guidelines can soon become 
out of step with the latest evidence. While we have dis-
cussed the challenge of international guidelines keeping 
apace of new CVOT data, committees developing local 
guidelines may have limited resources that make this an 
even more acute problem. Furthermore, clinicians — in 
particular PCPs — may be overburdened with numerous 
guideline updates calling on their attention; as such, the 
benefit from an evidence-based medicine standpoint of 
regularly producing updates may be countered by clinical 
apathy to yet-another-guideline, thus limiting effective 
communication.
Nevertheless, we believe that up-to-date, well-com-
municated guidelines are at the core of any success-
ful strategy to overcome clinical inertia. Therefore, it is 
incumbent upon us to be advocates for local guidelines 
that have simplified, clear and practical recommenda-
tions for busy clinicians to easily digest. It is crucial that 
these guidelines are centred on a key message of the need 
for a change in prescribing habits—robustly encourag-
ing treating physicians to use newer drug classes even 
where personal experience is limited, and conveying the 
urgency for eligible patients to receive agents with proven 
cardiorenal benefits, either by switching or as add-on 
therapies.
We also suggest putting in place a mechanism for trig-
gering frequent guidelines updates, if not already present, 
to ensure that the latest evidence is accounted for.
Collaborate on local education initiatives
We have acknowledged the lack of awareness that may 
be a key driver of clinical inertia. We can all have a role 
in creating and supporting the delivery of local educa-
tion initiatives, especially for PCPs, to ensure that the 
cardiorenal benefits of SGLT2is and GLP-1 RAs are 
more widely understood and appreciated. This should go 
alongside education on the central and interconnected 
roles of CV and renal risk in outcomes for patients with 
T2D, to persuade both PCPs and specialists that these 
risks demand more attention and need to be addressed 
independently of glycaemic control and obesity.
Deliver interdisciplinary care
By  providing more opportunities for interdisciplinary 
collaboration, we can increase exchange of expertise 
and ensure appropriate specialist attention earlier in 
the course of the disease. Although we note that cross-
speciality exchange on its own may not be sufficient to 
improve CV risk management [82], early involvement of 
a multidisciplinary team in T2D care has been shown to 
reap clinical benefits [110]. We agree with a recent call 
to cardiologists to become more involved in supporting 
diabetology and primary care colleagues in the manage-
ment of CV risk in patients with T2D [37]. As more data 
emerge on renal benefits with SGLT2i, we suggest that 
similar involvement from nephrologists will be required. 
A greater focus on interdisciplinary care will also better 
serve the growing understanding of T2D as part of a car-
diorenal–metabolic axis, with prevalent cardiorenal and 
metabolic comorbidities that each carry an incremental 
risk of MACE, HF and mortality [70, 71, 90].
Educate reimbursement authorities
Cost is evidently not the main barrier to uptake of 
SGLT2i and GLP-1 RA, as we have discussed; however, 
we recognise that for some healthcare providers it may 
be the deciding factor, and for others there may simply 
be no option to prescribe these agents, where local reim-
bursement rules do not support them. It is our view that 
clinicians can have an important role in dismantling cost 
barriers through ensuring that local professional guide-
lines are up-to-date, and engaging with local reimburse-
ment authorities to ensure that they are aware of the 
full evidence base supporting these guidelines. This will 
involve not only communicating the CVOT evidence but 
also advising on why the management of CV and renal 
risks are central to outcomes for patients with T2D, as 
well as decisive in healthcare resource utilisation. For 
example, a budget impact model in the UK found that 
treating 194,233 eligible patients with add-on empagliflo-
zin could lead to 2719 avoided heart failure events and 
5050 lives saved, with an estimated £19.5 m in cost sav-
ings for the NHS [111]. To assess the potential cost and 
resource savings with SGLT2i and GLP-1 RA, we believe 
it will be helpful for reimbursement practices to widely 
adopt the approach taken in international guidelines in 
separating the clinical requirements for glycaemic con-
trol and cardiorenal protection.
Facilitate patient empowerment while helping patients 
understand the goals of cardiorenal protection
Currently, too many patients with T2D lack awareness of 
CV risk factors [112, 113], and even those who are aware 
may not be optimally improving lifestyle factors to man-
age risk, or sufficiently accessing specialist care [113]. 
Page 13 of 17Schernthaner et al. Cardiovasc Diabetol          (2020) 19:185  
Similarly, studies suggest that less than 10% of affected 
patients are aware of the presence of CKD [114, 115], 
while only a minority of patients are aware that antidia-
betic agents are available that can reduce cardiorenal risk 
[113]. Possible adverse events as set out in the patient 
information leaflets for SGLT2i and GLP-1 RA may also 
be more of a concern to patients than the risks of CV 
events or the progression of renal disease without treat-
ment. The onus is thus on clinicians to ensure that each 
patient is fully appraised of the balance of risks with and 
without treatment; by doing so, patients will be empow-
ered to make informed decisions.
Patient education on cardiorenal risk may also have 
a role in defeating clinical inertia, through empower-
ing patients to discuss their health more fully with their 
clinicians—and motivating them to adopt lifestyle prac-
tices and ask for treatments that will provide cardiorenal 
protection. Discussions initiated by patients can lead to 
improved patient recall of treatment information [116], 
while patient feedback to physicians has been suggested 
to reduce clinical inertia [75].
What practical steps can we take to support patient 
empowerment? Encouraging motivated patients to pre-
pare questions before a consultation, and to bring a 
companion, can increase active participation in decision-
making [117]. Outside of the clinic, patient access to digi-
tal information can help to reduce the levels of CV risk 
factors, underscoring the importance of education [118].
Gauge individual physician performance to provide 
feedback and incentivise change
Working with clinicians to improve patient outcomes 
through audit and personal feedback processes may help 
clinicians to recognise biases or gaps in their knowl-
edge of guidelines [77, 119]. Feedback may involve chart 
audits, patient surveys or direct observation, and has 
been suggested to increase physician compliance with 
recommended care by up to 70% [77]. Indeed, a system-
atic review of computerised decision support systems 
for T2D in primary care found that these systems only 
improved patient outcomes when combined with perfor-
mance feedback to the PCP [120]. Incentives can also be 
incorporated into the process as additional motivation, 
such as institutional accreditation; adding incentives has 
been shown to be effective in a majority of studies [77]. 
Financial incentives have also been used with success 
in T2D, such as in the UK where the NHS introduced a 
“pay-per-performance” scheme linked to 129 indicators 
covering different areas including diabetes; this scheme 
was successful in improving outcomes for the selected 
indicators, in part due to increased DPP-4i use [121].
To apply these principles to addressing clinical iner-
tia in treating patients with T2D for cardiorenal risk, we 
suggest that “key performance indexes” are locally imple-
mented for treating physicians. Using electronic records, 
insurers or other organisations with responsibility for 
patient outcomes can track each physician’s usage of 
SGLT2i and GLP-1 RA in eligible, at-risk patients. Tar-
gets could be set for increasing the proportion of such 
patients receiving cardiorenal protective glucose-lower-
ing drugs over time, and physicians could be supported 
with individual feedback, such as suggesting switching to 
SGLT2i or GLP-1 RA in appropriate patients, and with 
computerised decision aids.
Conclusions
We are very fortunate to be living in the age of the 
CVOT; while colleagues practising before us had very 
limited options for improving cardiorenal outcomes, 
we now have several antidiabetic agents with proven 
cardiorenal benefits, and in some cases the ability to 
prolong life. Given this newfound fortune, it is regret-
table that many eligible, at-risk patients are still not 
receiving these agents, and may as a result suffer avoid-
able disease progression that incurs substantial use of 
healthcare resources and ultimately premature death. 
As clinical inertia has remained strong in the face of 
5 years of accumulating evidence showing the potential 
of certain SGLT2i and GLP-1 RA to reduce cardiorenal 
events in at-risk patients, we are concerned that the 
status quo will continue. To illustrate the gravity of the 
situation for patients, we believe that inadequate car-
diorenal protection in T2D should now be recognised 
as a crisis.
As such, we call upon our colleagues to join us in 
working together across specialities at a local, national 
and international level to address clinical inertia; ensure 
guidelines are continuously updated as needed; and 
support initiatives that will increase access to antidia-
betic agents with proven cardiorenal benefit to patients 
on the basis of cardiorenal risk, and independently of 
HbA1c goals. Only then will the full promise of CVOT 
evidence be realised for our patients with T2D.
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